Inorganic Non-Active Ingredients TRIZ Cases

See how a water-based edible ink with titanium oxide, dispersant, and low-molecular-weight poly

A ferromagnetic mesh and meltable barrier enable rapid external magnetic shutdown of implantable drug flow without surgical explantation.

A ferromagnetic mesh melts a hydrophobic barrier to seal flow holes, enabling rapid implant drug shutoff without surgical explantation.

A ferromagnetic mesh melts a hydrophobic barrier to quickly block implant drug flow without surgical explantation.

An external magnetic field heats a ferromagnetic mesh to melt and close flow holes, rapidly stopping implanted drug delivery without explantation.

Transient anti-idiotypic antibody blocking helps high-affinity tumor antibodies penetrate solid tumors more evenly without relying on low affinity or high doses.

Using precipitated calcium carbonate in a film-forming shell, this case shows how capsules cut light transmittance while retaining strength.

A loading-aid liposome improves BCL inhibitor encapsulation and release control to treat cancer with less thrombocytopenia and toxicity.

EDTA, TRIS, and salt stabilize RNA and mRNA vaccines at ambient temperatures, reducing cold-chain storage and transport burdens.

Engineered polypeptides convert 3-keto-DON into non-toxic 3-epi-DON with high stereoselectivity, improving trichothecene detoxification.

Specific lipid ratios in LNPs protect unstable mRNA, improve cellular uptake, and drive stronger vaccine immune responses.

A boronate template ion enables scalable delta-cyclodextrin synthesis with high yield and purity, avoiding column chromatography.

A cross-type release film and waterproof-breathable adhesive layer help this edged cataplasm stay attached on joints, even after bathing.

A phosphate-buffered artificial vitreous humor maintains physiological pH and composition for more reliable in-vitro drug stability and release testing.

Suspending and taste-masking excipients keep topiramate oral liquid stable, easy to redisperse, and more palatable for uniform dosing.

An actinium-225 PSMA I&T formulation uses ascorbate and acid to maintain purity for 120 hours while reducing hematological and salivary toxicity.

An Actinium-225 PSMA I&T formulation with ascorbic acid and hydrochloric acid improves shelf-life stability while lowering toxicity in mCRPC therapy.

Buffered 67Cu aqueous formulations with gentisic acid, ethanol, and ascorbic acid limit radiolysis and maintain radiochemical purity for 96 hours.

A non-aqueous ready-to-use hydroxyurea suspension stays stable at room temperature, improving pediatric dosing without refrigeration.

Arginine or lysine with phosphate buffer and Poloxamer 188 keeps concentrated antibody liquids stable, low-aggregate, and injectable.

A whisked egg white foam matrix improves solubility and rapid release of oil-soluble actives while avoiding solid taste and dental issues.

A pH 5-6 histidine-buffered anti-Cx43 antibody formulation uses polysorbate 80 and sucrose to prevent aggregation during storage.

Polyglutamated alpha tetrahydrofolate liposomes improve cellular uptake and retention, helping boost chemotherapy efficacy while reducing side effects.

Supercritical CO2 extraction standardizes saw palmetto fatty acid profiles, avoiding residual solvents and reducing lot-by-lot bioassays.

Formic-acid pH gradients improve weak acid drug encapsulation in liposomes while avoiding bicarbonate-driven instability and premature release.

Multipath reflections become indoor location fingerprints, letting RF point clouds localize people and detect actions without ghost tracking errors.

ZnO and CaCO3 replace TiO2 in hard capsule shells to keep white opacity while improving elasticity, reducing fragility, and lowering process energy.

L-methionine, sucrose, and polysorbate-80 protect ILT7-binding proteins from light-driven oxidation and aggregation at high concentration.

A dual-action composition boosts ADH-driven ethanol metabolism while scavenging acetaldehyde to lower toxicity and oxidative stress.

A reparixin powder blend uses viscosity, wetting, and dispersing agents to form a stable, easily resuspended aqueous suspension.

A mucoadhesive alcaftadine nasal composition improves mucosal retention for faster rhinitis relief with less unpleasant taste and fewer systemic side effects.

A buffered surfactant formulation stabilizes anti-KIR3DL2 antibody solutions by limiting particle formation, aggregation, and degradation.

Antioxidants in the osmotic solute composition suppress radiation-induced aldehydes, protecting active agents during gamma sterilization.

A stable anti-PVRIG, anti-TIGIT, and pembrolizumab formulation addresses multi-treatment-resistant cancer by boosting IFNγ and lowering IL-6 and IL-8.

Ozone oxidation and alkaline horn sonication break nanodiamond aggregates into sub-10 nm particles without metal contamination.

Ascorbate-stabilized 225Ac-PSMA I&T lowers hematological and salivary toxicity while maintaining purity and stability for prostate cancer therapy.

Blocking TIGIT-PVRIG inhibitory signaling with anti-TIGIT and anti-PVRIG antibodies restores T-cell and NK cell anti-tumor activity.

An intermediate coating with alkaline and release-acceleration agents cuts enteric lag time and enables rapid duodenal drug release at pH 3-6.

Calcium salt treatment forms a pectin gel network that keeps softgel shells intact in acid yet allows controlled disintegration at higher pH.

Engineered FcRn antagonist Fc variants block IgG recycling through pH-dependent FcRn binding, rapidly lowering serum IgG in autoimmune disorders.

An egg white foam matrix improves solubility and rapid mucosal release of oil-soluble functional ingredients while avoiding harsh processing.

A swellable oral dosage form expands from a compact state in the stomach to improve retention time and stabilize drug delivery despite GI variability.

D-lactic acid and polyols stabilize vancomycin in a ready-to-administer aqueous solution, avoiding frozen storage and thawing.

Water-based edible ink with titanium oxide, dispersant, and low-MW polysaccharide improves wettability, drying, and print resumability on tablets.

Targets DNAM-axis immune evasion with a stable anti-PVRIG, anti-TIGIT, and anti-PD-1 liquid formulation to boost T-cell activation.

Combining anti-HER2 targeting with cytotoxic payloads improves efficacy in resistant HER2-positive cancers while reducing key treatment toxicities.

Buffered retifanlimab compositions use acetate, sucrose, and polysorbate 80 to preserve purity, pH, and shelf-life for cancer treatment.

Bean and cereal starch blends create a gluten-free pet medication aid that masks bitter taste, supports digestion, and avoids allergy risks.

When faster ethanol metabolism raises acetaldehyde, this dual-action formulation combines ADH with scavengers to address clearance and toxicity together.

Terminal sterilization and pH 5.5–8 aqueous formulation help reduce reconstitution steps, particulates, and injection-site discomfort.

Existing sotalol suspensions offer limited stability for patients unable to swallow solids; optimized oral solutions remain stable beyond 4 months.

Polymer-conjugated lipids and ionic loading aids improve encapsulation efficiency while liposomal delivery reduces systemic toxicity.

High-concentration humanized anti-CD40 formulations use polysorbate 20, acetate, and polar excipients to limit aggregation and extend shelf-life.

Acidic mixing prevents precipitate formation during boric acid crosslinking, ensuring stable biomedical hydrogels.